These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 36146629)
1. Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy. Liu X; Zhao J; Li X; Lao F; Fang M Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146629 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic vaccinia virus and cancer immunotherapy. Xu L; Sun H; Lemoine NR; Xuan Y; Wang P Front Immunol; 2023; 14():1324744. PubMed ID: 38283361 [TBL] [Abstract][Full Text] [Related]
3. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. Cook J; Acosta-Medina AA; Peng KW; Lacy M; Russell S Cancer Treat Res Commun; 2021; 29():100473. PubMed ID: 34673439 [TBL] [Abstract][Full Text] [Related]
5. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618 [TBL] [Abstract][Full Text] [Related]
6. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Pelin A; Boulton S; Tamming LA; Bell JC; Singaravelu R Expert Opin Biol Ther; 2020 Sep; 20(9):1083-1097. PubMed ID: 32297534 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Feola S; Russo S; Ylösmäki E; Cerullo V Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. Heidbuechel JPW; Engeland CE J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363 [TBL] [Abstract][Full Text] [Related]
9. Arming oncolytic viruses to leverage antitumor immunity. de Gruijl TD; Janssen AB; van Beusechem VW Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450 [TBL] [Abstract][Full Text] [Related]
10. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Yun CO; Hong J; Yoon AR Front Immunol; 2022; 13():953410. PubMed ID: 36091031 [TBL] [Abstract][Full Text] [Related]
11. Virotherapy Research in Germany: From Engineering to Translation. Ungerechts G; Engeland CE; Buchholz CJ; Eberle J; Fechner H; Geletneky K; Holm PS; Kreppel F; Kühnel F; Lang KS; Leber MF; Marchini A; Moehler M; Mühlebach MD; Rommelaere J; Springfeld C; Lauer UM; Nettelbeck DM Hum Gene Ther; 2017 Oct; 28(10):800-819. PubMed ID: 28870120 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517 [TBL] [Abstract][Full Text] [Related]
13. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them. Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087 [TBL] [Abstract][Full Text] [Related]
14. Viruses as nanomedicine for cancer. Badrinath N; Heo J; Yoo SY Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350 [TBL] [Abstract][Full Text] [Related]
15. Design and application of oncolytic viruses for cancer immunotherapy. Ylösmäki E; Cerullo V Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424 [TBL] [Abstract][Full Text] [Related]